Scandion Oncology is a Danish biotech company developing treatments aimed at counteracting cancer drug resistance. Currently in phase II with its top candidate SCO-101, the company is raising capital through a rights issue and has partnering in its sights. Scandion Oncology’s CEO Bo Rode Hansen joined BioStock via video link to tell us more about the company and what makes SCO-101 first-in-class drug candidate.

See the company presentation and Q&A below:

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev